Teva Canada Limited, Medincell's Affiliate, Gains Canadian Approval for Risperidone LAI for Schizophrenia Treatment
I'm PortAI, I can summarize articles.
Teva Canada Limited，作為 Medincell 合作伙伴 Teva Pharmaceutical Industries Ltd.的附屬公司，已獲得加拿大衞生部對長效利培酮（risperidone LAI）的監管批准，該藥物用於治療成人精神分裂症。這一批准標誌着製藥行業的重要進展，增強了精神分裂症患者的治療選擇
Teva Canada Limited，作為 Medincell 合作伙伴 Teva Pharmaceutical Industries Ltd.的附屬公司，已獲得加拿大衞生部對用於治療成人精神分裂症的利培酮長效注射劑的監管批准。免責聲明：本新聞簡報由公共技術公司（PUBT）使用生成性人工智能創建。儘管 PUBT 努力提供準確和及時的信息，但此 AI 生成的內容僅供參考，不應被解讀為財務、投資或法律建議。Medincell SA 於 2025 年 9 月 23 日發佈了用於生成本新聞簡報的原始內容，並對其中包含的信息承擔全部責任。© 版權 2025 - 公共技術公司（PUBT）原始文檔：這裏
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments